LCR Clinical Research   Report issue

For profit Phase 2
Founded: Prague Czech Republic (2004)

Organization Overview

First Clinical Trial
2013
NCT01621256
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

LCR Leading Clinical Research s.r.o.

Active Ingredients

Drugs in Phase 2 Trials (3)

ancrod (Viprinexun) (1 trial)

sodium chloride (1 trial)

vs-505 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Deafness (Phase 2)

Ear Diseases (Phase 2)

Hearing Disorders (Phase 2)

Hearing Loss (Phase 2)

Hearing Loss, Sensorineural (Phase 2)

Hyperphosphatemia (Phase 2)

Kidney Diseases (Phase 2)

Kidney Failure, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3